Industry & Business

Bristol-Myers Squibb to sell Swords manufacturing facility to SK Biotek Co., Ltd.

 Breaking News
  • Arkphire Secures New Investment IT solutions and networking company, Arkphire, has announced that Bregal Milestone, a private capital firm, has completed an investment into the business. The investment by Bregal Milestone comes from their new €400 million pan-European fund dedicated to investing in high-growth European companies. Typical commitments from Bregal Milestone range from €20 million to €60 million. Arkphire provides [...]...
  • Government Investment in Research & Development Amounts to Over €750 Million in 2018 The latest figures on Government investment in research and development (R&D), published by the Department of Business, Enterprise and Innovation, show that over €750 million is estimated to have been invested in R&D in 2018. The data in The Research and Development Budget 2017-2018 publication is compiled from a comprehensive survey of thirty Government Departments [...]...
  • Smart Dublin in Partnership With Enterprise Ireland Award 21 New Innovation Contracts Approximately €700,000 is to be awarded to companies under Enterprise Ireland’s Small Business Innovation Research (SBIR) initiative which will enable them explore innovative solutions to address challenges faced by Local Authorities. 21 companies have been awarded Phase One funding to progress the feasibility of their solutions. Phase One funding will allow each recipient to carry [...]...
  • Tourism Industry Barometer Reflects Buoyant Year But Hints at Brexit Concerns Tourism performance throughout 2018 continues to be on a strong footing, according to the latest Fáilte Ireland Tourism Barometer. The survey of more than 500 tourism businesses around the country shows over half of the tourism industry is reporting their business to be up, with two thirds (64%) saying that tourism agency supports have been [...]...
  • Glanbia to Acquire SlimFast For $350 Million Glanbia, the global nutrition group, has agreed to acquire SlimFast and other brands for $350 million from the owners KSF Holdings LLP and HNS Intermediate Corporation. SlimFast is a leading weight management and health & wellness brand family distributed primarily in the food, drug, mass and club (FDMC) channel in the US and UK. It [...]...

Bristol-Myers Squibb to sell Swords manufacturing facility to SK Biotek Co., Ltd.

Bristol-Myers Squibb to sell Swords manufacturing facility to SK Biotek Co., Ltd.
June 20
09:00 2017

IDA Ireland has welcomed the joint-announcement by Bristol-Myers Squibb and South Korean company SK Biotek Co., Ltd of agreement for SK Biotek to acquire Bristol-Myers Squibb’s Active Pharmaceutical Ingredients (API) Manufacturing Facility in Swords, Co Dublin.

The announcement confirms that the two companies have signed a definitive purchase agreement for Bristol-Myers Squibb to sell its small molecule active pharmaceutical ingredient manufacturing facility in Swords to SK Biotek, a wholly-owned subsidiary of SK Holdings, based in Seoul, South Korea. All jobs on the Swords site dedicated to API Operations will transition to SK Biotek.  The companies intend to complete the deal by the fourth quarter 2017, at which time SK Biotek will continue to manufacture the current portfolio of small molecule pharmaceutical products at the site.

The Swords facility currently manufactures active pharmaceutical ingredients (APIs) for a number of medicines including Bristol-Myers Squibb’s and Pfizer’s Eliquis. Through the years, the site has produced medicines that have helped millions of people in the fight against serious diseases such as cancer, cardiovascular disease, hepatitis, HIV/AIDS and psychiatric disorders. SK Biotek will operate the plant as a stand-alone Contract Development Manufacturing Organization (CDMO), and intends to add marketing, research and development (R&D) talent, and invest in upgrades to bring additional capacity to the site.

Bristol-Myers Squibb and SK Biotek anticipate that the transaction will close during the fourth quarter of 2017. Closing of the transaction is subject to SK Biotek’s receipt of certain environmental permits in addition to other customary closing conditions. The transaction has been approved by the boards of directors of both companies.

Speaking of the acquisition Junku Park Ph. D., chief executive officer of SK Biotek, commented “This transaction is an important step to achieve our goal of becoming a leading global CDMO. It allows us to enhance technological and manufacturing capacity and build long-term partnerships with existing and new customers. We have chosen to invest in Ireland because of the welcoming business environment and the exceptionally talented workforce, and we look forward to growing our presence in Swords in the coming years.  We are very pleased to welcome the Swords facility to SK Biotek.”

Lou Schmukler, president, Global Product Development & Supply, Bristol-Myers Squibb  said; “We value our partnership with SK Biotek and believe today’s agreement will continue the vital role the Swords facility plays for its employees, the community and patients.

Today’s agreement is an important step in the ongoing evolution of our manufacturing network to support the company’s innovative portfolio. Our continued investment in Ireland is critical for our ability to deliver transformational medicines to patients, both through the increased biologics capabilities we are building in Cruiserath and our ongoing commercial and business presence in Dublin.”

SK Biotek and Bristol-Myers Squibb have an established relationship in pharmaceutical manufacturing and supply. SK Biotek has been a supplier to Bristol-Myers Squibb for 10 years, and a key producer of commercial API starting materials and chemical intermediates.  With state of the art R&D facilities, multi-purpose manufacturing plants and a deep foundation in manufacturing technologies, SK has provided a high degree of flexibility and quality service to Bristol-Myers Squibb and continues to be a trusted partner from early phase development through to commercial production.

Commenting on the announcement CEO of IDA Ireland Martin Shanahan said: “I am delighted to welcome the South Korean company SK Biotek to Ireland. Great credit is acknowledged to both companies for having achieved an acquisition agreement which enables continuity of active pharmaceutical ingredients production and protects jobs on a site which has been involved in pharmaceuticals production for over 50-years. Ireland prides itself in delivering manufacturing excellence in the pharma industry and is home to nine of the ten top global pharmaceutical companies. I wish SK Biotek every success as they further develop the Swords facility in Dublin.”

About Author

editor

editor

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4